Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

In a significant milestone for neurotechnology, Science Corporation has successfully implanted its PRIMA vision-restoration system into the first patient suffering from Stargardt disease. This inherited condition, which progressively erodes central vision, has long been considered incurable. The announcement was made by Max Hodak, the company’s CEO and a co-founder of Neuralink, during a keynote appearance at TechCrunch Disrupt.

Expanding the Definition of Brain-Computer Interfaces

For Hodak, the PRIMA implant is far more than a specialized medical device; it represents a foundational step in his company’s broader mission to develop sophisticated brain-computer interfaces (BCIs). By viewing the retina as an extension of the central nervous system, Science Corporation is positioning its work within a spectrum of neural prosthetics.

“The retina is part of the central nervous system. We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs,” Hodak explained during his presentation.

While the PRIMA system is already commercially available in Europe for patients experiencing vision loss due to geographic atrophy—a severe manifestation of age-related macular degeneration—the company is now aggressively testing its efficacy for Stargardt disease. This condition specifically targets the outer retina, leading to the death of light-sensing cells while often leaving the inner retina, which transmits signals to the brain, intact. The result is a central blind spot that expands over time, affecting approximately 150,000 individuals globally.

How the PRIMA System Functions

The technology operates on a principle of electrical stimulation. Because the brain interprets vision as electrical activity traveling down the optic nerve, the PRIMA system acts as an artificial photoreceptor array.

• The Procedure: Patients undergo a one-hour surgical intervention to place a 2mm x 2mm chip beneath the retina.
• The Interface: Users wear specialized glasses equipped with cameras that capture the visual environment and transmit that data to the implanted chip.
• The Result: The patient receives high-contrast, black-and-white visual information directly into the central field of vision.

The first patient, treated at the Sydney Eye Hospital in Australia, demonstrated remarkable progress. During initial rehabilitation sessions, the patient was able to identify individual letters and, by the second session, successfully read a full word.

The Path Toward Native Acuity

Despite the success, Hodak remains candid about the current limitations of the technology. He likens the current visual experience to "looking through a straw." The field of view is narrow, and while the images are sharp, they lack the complexity of natural color vision.

To bridge the gap between current capabilities and human-level sight, Science Corporation is focusing on two primary engineering challenges: 1. Expanding the Field of View: Developing larger implants that can conform to the natural curvature of the human eye. 2. Increasing Resolution: Shrinking the size of the electrodes to achieve a level of detail that mimics native biological acuity.

Hodak expressed confidence in the company’s trajectory, noting that a "next-generation" device is slated for human trials within the next year. He anticipates that within five years, the technology will be capable of providing vision that closely approximates natural sight.

Beyond Vision: The Long-Term Vision for BCIs

When Hodak founded Science Corporation in 2021, the goal was never limited to ophthalmology. The company is building a sustainable business model by solving immediate, high-impact medical problems, but its long-term ambitions are rooted in the fundamental understanding of the human mind.

Unlike the Neuralink approach, which involves inserting electrodes directly into brain tissue, Science Corporation’s BCI sensor is designed to be implanted inside the skull, resting atop the brain. This less invasive methodology is intended to address a variety of neurological conditions.

Future Clinical Applications

• Neurodegenerative Diseases: The company is preparing to announce its first clinical indication for a well-known neurodegenerative condition.
• Stroke Recovery: By establishing connections in deep brain areas, the company aims to potentially "add" new cortical areas to compensate for tissue lost to strokes.
• Health Span Extension: Hodak envisions a future where BCIs are not just for the severely ill, but are utilized by aging populations to maintain cognitive and physical health.

“The long-term mission of the company is to understand how the brain creates the mind and to learn to build engineered brains,” Hodak stated. While the company is not currently designing devices for healthy, younger adults, Hodak believes that by the time people reach the age of 60 or 70, some form of BCI technology will become a standard tool for extending not just the human lifespan, but the quality of one's "health span."

As Science Corporation continues its clinical trials, the medical community will be watching closely to see if this marriage of advanced neural engineering and ophthalmology can truly deliver on its promise to restore sight to the blind and, eventually, unlock the deeper mysteries of the human brain.